Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary

NCT05296512 is registered in ClinicalTrials.gov with Elizabeth K. Lee MD as lead sponsor.

NCT NCT05296512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05296512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary
Lead sponsor
Elizabeth K. Lee MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 23, 2022
Completion date
November 15, 2028
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gynecologic cancer, ovarian clear cell carcinoma